On Dec. 26, 2017, specialty pharmaceutical company Mallinckrodt announced that it has agreed to acquire Sucampo Pharmaceuticals, a biopharmaceutical company, in a deal valued at approximately $1.2 billion. The transaction, which was approved by the boards of directors of both companies, includesOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.